1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Direct Link:
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study
Article first published online: 31 AUG 2006
DOI: 10.1002/art.22070
Copyright © 2006 by the American College of Rheumatology
Additional Information
How to Cite
Weinblatt, M., Combe, B., Covucci, A., Aranda, R., Becker, J. C. and Keystone, E. (2006), Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis & Rheumatism, 54: 2807–2816. doi: 10.1002/art.22070
Publication History
- Issue published online: 31 AUG 2006
- Article first published online: 31 AUG 2006
- Manuscript Accepted: 9 JUN 2006
- Manuscript Received: 15 FEB 2006
Funded by
- Bristol-Myers Squibb
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , , , , 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features, Arthritis Care & Research, 2011, 63, 4
- 2, A rheumatoid arthritisben alkalmazott biológiai kezelések hatásossága az ACR70-végpont szerint: indirekt összehasonlÃtás és metaregresszió Bayes-modell alkalmazásával, Orvosi Hetilap, 2011, 152, 23, 919
- 3, , Abatacept: a biologic immune modulator for rheumatoid arthritis, Expert Opinion on Biological Therapy, 2011, 11, 8, 1113
- 4, , , Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events, Autoimmunity Reviews, 2011, 11, 1, 56
- 5, , , , , , Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial, Arthritis & Rheumatism, 2011, 63, 3Direct Link:
- 6
- 7, , , Infectious Complications Associated with Immunomodulating Biologic Agents, Hematology/Oncology Clinics of North America, 2011, 25, 1, 117
- 8, , , , , , Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review, Rheumatology, 2011, 50, 12, 2297
- 9, , , Perioperative Management of Biologic Agents Used in Treatment of Rheumatoid Arthritis, American Journal of Therapeutics, 2011, 18, 5, 426
- 10, , , , , , , , , , , , , , , , , , , , , , , Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA, Current Medical Research and Opinion, 2011, 27, 2, 315
- 11, , , Rheumatoid arthritis: What is refractory disease and how to manage it?, Autoimmunity Reviews, 2011, 10, 11, 707
- 12, , , , , , , , , , , Risk of infections in rheumatoid arthritis patients treated with tocilizumab, Rheumatology, 2011,
- 13, , Safety of biologic therapy in rheumatoid arthritis, Nature Reviews Rheumatology, 2011, 7, 11, 639
- 14, , , , , The genetics of alopecia areata: What's new and how will it help our patients?, Dermatologic Therapy, 2011, 24, 3Direct Link:
- 15, , , , , , , , The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials, Scandinavian Journal of Rheumatology, 2011, 40, 1, 1
- 16, , , , , , The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: AÂ systematic review and meta-analysis of randomized controlled trials, Journal of the American Academy of Dermatology, 2011, 64, 6, 1035
- 17, , The risk of tuberculosis in patients treated with TNF antagonists, Expert Review of Clinical Immunology, 2011, 7, 3, 329
- 18
- 19
- 20, , , Co-stimulation and T cells as therapeutic targets, Best Practice & Research Clinical Rheumatology, 2010, 24, 4, 463
- 21, , Die Bedeutung von Biologika bei der Therapie der SoJIA (Morbus Still), Zeitschrift für Rheumatologie, 2010, 69, 6, 505
- 22, , , Infectious Complications Associated with Immunomodulating Biologic Agents, Infectious Disease Clinics of North America, 2010, 24, 2, 285
- 23, , , , , Pulmonary Manifestations of Rheumatoid Arthritis, Clinics in Chest Medicine, 2010, 31, 3, 451
- 24, , Rheumatoid arthritis therapy: Advances from bench to bedside, Autoimmunity, 2010, 43, 7, 478
- 25, , , Safety profile of abatacept in rheumatoid arthritis: A review, Clinical Therapeutics, 2010, 32, 11, 1855
- 26, , , Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis, Autoimmunity Reviews, 2010, 9, 8, 574
- 27, , , , The older rheumatoid arthritis patients: who are they and how should they be treated?, Aging Health, 2010, 6, 5, 533
- 28, The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis, Seminars in Arthritis and Rheumatism, 2010, 39, 5, 327
- 29, , , , , , , , , , , , , , , Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis, Reumatolog Ãa Cl Ãnica (English Edition), 2010, 6, 1, 23
- 30, , , Abatacept in the treatment of rheumatoid arthritis, Expert Review of Clinical Immunology, 2009, 5, 1, 9
- 31, , , , , , , , , , , , , , , Abatacept therapy and safety management, Joint Bone Spine, 2009, 76, S3
- 32, , Abatacept, a Novel CD80/86–CD28 T Cell Co-stimulation Modulator, in the Treatment of Rheumatoid Arthritis, Basic & Clinical Pharmacology & Toxicology, 2009, 104, 4Direct Link:
- 33, Assessing adequate treatment response in patients with rheumatoid arthritis, Clinical Therapeutics, 2009, 31, 6, 1219
- 34, , , B-cell-directed therapies for autoimmune disease, Nature Reviews Rheumatology, 2009, 5, 8, 433
- 35, , , , , , , Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+T cells, Biochemical and Biophysical Research Communications, 2009, 386, 2, 327
- 36, , , , Costimulation blockade in rheumatic diseases: where we are?, Current Opinion in Rheumatology, 2009, 21, 3, 244
- 37, , , , Incidence and nature of infectious disease in patients treated with anti-TNF agents, Autoimmunity Reviews, 2009, 9, 2, 67
- 38, , Infectious Complications of Biologic Agents, Rheumatic Disease Clinics of North America, 2009, 35, 1, 183
- 39, , , Modulation of T-Cell Co-Stimulation in Rheumatoid Arthritis, Clinical Drug Investigation, 2009, 29, 3, 185
- 40, , , , Neue Option in der Behandlung der rheumatoiden Arthritis: Abatacept, ein selektiver Modulator der T-Zell-Kostimulation, Wiener Medizinische Wochenschrift, 2009, 159, 3-4, 70
- 41
- 42, Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab, Seminars in Arthritis and Rheumatism, 2009, 38, 4, 265
- 43, , , , Targeting lymphocyte activation to treat rheumatoid arthritis, Joint Bone Spine, 2009, 76, 4, 327
- 44
- 45
- 46, , , Abatacept and serious respiratory infections in patients with previous lung disease, Clinical Rheumatology, 2008, 27, 12, 1569
- 47, , Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis, Expert Opinion on Biological Therapy, 2008, 8, 1, 115
- 48, , , , , , , , , , , , , , , , , , , , , , American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis Care & Research, 2008, 59, 6Direct Link:
- 49, B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data, Current Opinion in Neurology, 2008, 21, Suppl 1, S19
- 50, , , , , Biologics and heart failure in rheumatoid arthritis: are we any wiser?, Current Opinion in Rheumatology, 2008, 20, 3, 327
- 51, , Challenges in the management of rheumatoid arthritis in developing countries, Best Practice & Research Clinical Rheumatology, 2008, 22, 4, 621
- 52, , , , , , , , Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis, Clinical Rheumatology, 2008, 28, 4, 403
- 53, Costimulation blockade in autoimmunity and transplantation, Journal of Allergy and Clinical Immunology, 2008, 121, 2, 299
- 54, , , Cytokines as Therapeutic Targets: Advances and Limitations, Immunity, 2008, 28, 4, 440
- 55, , Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis, Zeitschrift für Rheumatologie, 2008, 67, 7, 614
- 56, Improving patient outlook in rheumatoid arthritis: Experience with abatacept, Journal of the American Academy of Nurse Practitioners, 2008, 20, 10Direct Link:
- 57, , , Lupus systémique : les traitements du futur, La Revue de Médecine Interne, 2008, 29, 9, 718
- 58, , Malignancy and biologic therapy in rheumatoid arthritis, Current Opinion in Rheumatology, 2008, 20, 3, 334
- 59, , , , Mycobacterial disease in patients with rheumatic disease, Nature Clinical Practice Rheumatology, 2008, 4, 12, 649
- You have free access to this content60, Pathogenesis of Asthma, Clinical & Experimental Allergy, 2008, 38, 6Direct Link:
- 61, , Rheumatoid Arthritis: Beyond Tumor Necrosis Factor-α Antagonists, B Cell Depletion, and T Cell Blockade, American Journal of Therapeutics, 2008, 15, 1, 53
- 62, , Risk of skin cancer in the drug treatment of rheumatoid arthritis, Expert Opinion on Drug Safety, 2008, 7, 5, 539
- 63, , Takayasu’s arteritis, Current Treatment Options in Cardiovascular Medicine, 2008, 10, 2, 164
- 64, Targeted therapy in rheumatoid arthritis, Expert Opinion on Drug Discovery, 2008, 3, 3, 329
- 65, Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future, Rheumatology, 2008, 47, 10, 1461
- 66, , , , , Toward a Non-Empirical Treatment for Rheumatoid Arthritis Based on Its Molecular Pathogenesis, Reumatolog Ãa Cl Ãnica (English Edition), 2008, 4, 1, 19
- 67, , , Update on the use of analgesics versus nonsteroidal anti-inflammatory drugs in rheumatic disorders: risks and benefits, Current Opinion in Rheumatology, 2008, 20, 3, 239
- 68, , , Abatacept in the treatment of rheumatoid arthritis, International Journal of Clinical Practice, 2007, 61, 3Direct Link:
- 69, Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis, Advances in Therapy, 2007, 24, 2, 333
- 70, , , Abatacept: A Novel Treatment for Moderate-to-Severe Rheumatoid Arthritis, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007, 27, 12Direct Link:
- 71, Abatacept: a novel treatment for rheumatoid arthritis, Expert Opinion on Pharmacotherapy, 2007, 8, 14, 2371
- 72, , , Adverse reactions and safety of newer disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, Adverse Drug Reaction Bulletin, 2007, &NA;, 242, 927
- 73, , , Clinical Pharmacokinetics and Use??of??Infliximab, Clinical Pharmacokinetics, 2007, 46, 8, 645
- 74Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2007, 16, 4Direct Link:
- 75
- 76, , Monoclonal Antibody Therapeutics and Risk for Infection, The Pediatric Infectious Disease Journal, 2007, 26, 11, 1049
- 77, , , , , New therapies for treatment of rheumatoid arthritis, The Lancet, 2007, 370, 9602, 1861
- 78, , , Rheumatoid arthritis and the evolution of therapy: from symptomatic to bench-to-bedside biological drugs, Future Rheumatology, 2007, 2, 2, 143
- 79, , T Cell Costimulation: A Rational Target in the Therapeutic Armamentarium for Autoimmune Diseases and Transplantation, Annual Review of Medicine, 2007, 58, 1, 347
- 80
- 81, , The role of T cells in rheumatoid arthritis: new subsets and new targets, Current Opinion in Rheumatology, 2007, 19, 3, 284
- 82, , Tumor necrosis factor as a therapeutic target of rheumatologic disease, Expert Opinion on Therapeutic Targets, 2007, 11, 11, 1369
- 83, Using the new biologic therapies in rheumatoid arthritis: practical aspects, Future Rheumatology, 2007, 2, 5, 475
- 84, , Drug Insight: abatacept for the treatment of rheumatoid arthritis, Nature Clinical Practice Rheumatology, 2006, 2, 12, 654
- 85, , Abatacept for rheumatoid arthritis, The Cochrane Library,Direct Link:
- 86, , , , , , , , , , , , , , , , , , , , , Adverse effects of biologics: a network meta-analysis and Cochrane overview, The Cochrane Library,Direct Link: